Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer
- 31 December 2000
- journal article
- Published by Elsevier in The Breast
- Vol. 9 (6) , 338-342
- https://doi.org/10.1054/brst.2000.0170
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancerAnti-Cancer Drugs, 1999
- Treatment of Breast CancerNew England Journal of Medicine, 1998
- Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results.Journal of Clinical Oncology, 1997
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.Journal of Clinical Oncology, 1996
- Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.Journal of Clinical Oncology, 1996
- Advanced breast cancer: a phase II trial with gemcitabine.Journal of Clinical Oncology, 1995
- High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.Journal of Clinical Oncology, 1995
- Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer PatientsJNCI Journal of the National Cancer Institute, 1994
- A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.Journal of Clinical Oncology, 1991